Acne vulgaris affects a significant portion of the population, often necessitating prescription-strength treatments. The recent FDA approval of adapalene 0.1% gel for over-the-counter (OTC) use marks a shift in accessibility for a well-established topical retinoid, potentially altering initial management strategies for many patients.
Topical retinoids are a cornerstone of acne treatment, recommended as first-line therapy for most forms of acne, including comedonal, papular, and pustular lesions.1 Their mechanism of action involves normalising follicular keratinisation, reducing microcomedone formation, and exerting anti-inflammatory effects.2 Until recently, all retinoids, including adapalene, tazarotene, and tretinoin, required a prescription, limiting direct patient access and often delaying initiation of effective therapy. The FDA's decision to approve adapalene 0.1% gel for OTC availability addresses this barrier, making it the first retinoid to transition from prescription-only to OTC status. This move follows a trend of making certain effective dermatological treatments more accessible to the public, provided they meet stringent safety and efficacy criteria for non-prescription use.3
The OTC Switch for Adapalene 0.1% Gel
The FDA's approval of adapalene 0.1% gel for OTC use was based on a comprehensive review of clinical data, including efficacy, safety, and consumer studies. These studies were designed to assess whether consumers could understand and follow the product's labelling instructions without the guidance of a healthcare professional. Key considerations for an OTC switch include a favourable safety profile, a low potential for misuse or abuse, and the ability for consumers to self-diagnose and treat the condition effectively.4
Clinical trials supporting the efficacy of adapalene 0.1% gel for acne treatment have consistently demonstrated its ability to reduce inflammatory and non-inflammatory lesions. For instance, a 12-week randomised, double-blind, vehicle-controlled study involving 237 patients with mild to moderate acne showed that adapalene 0.1% gel significantly reduced total lesion counts by 45% compared to 20% with vehicle (p < 0.001). Inflammatory lesion counts decreased by 50% versus 25% (p < 0.001), and non-inflammatory lesion counts by 40% versus 15% (p < 0.001).5 Another large-scale study, a 12-week, multicentre, randomised, double-blind, parallel-group trial, compared adapalene 0.1% gel with tretinoin 0.025% gel in 277 patients. Both treatments were effective, with adapalene showing comparable efficacy and a superior tolerability profile, particularly regarding erythema and scaling.6
The safety profile of adapalene 0.1% gel, when used as directed, is well-established. Common adverse events include transient skin irritation, dryness, scaling, and erythema, often referred to as retinoid dermatitis. These effects are typically mild to moderate and tend to decrease with continued use as the skin adapts.7 Photosensitivity is another known side effect, necessitating sun protection measures. Consumer studies conducted for the OTC switch specifically evaluated whether individuals could correctly interpret warnings regarding these side effects and implement appropriate mitigation strategies, such as using sunscreen. The data indicated that consumers could understand these instructions, supporting the safety argument for non-prescription availability.4
The approval of adapalene 0.1% gel for OTC use provides a new option for individuals seeking to manage their acne without a prescription. This accessibility may lead to earlier intervention for some patients, potentially preventing the progression of acne and reducing the risk of scarring. However, it also places a greater responsibility on consumers to adhere to product instructions and recognise when professional medical advice is warranted, particularly for severe or recalcitrant acne. The FDA's decision underscores the balance between expanding access to effective treatments and ensuring public safety through clear labelling and consumer education.3
The OTC switch for adapalene 0.1% gel represents a significant shift in the landscape of acne management. For general practitioners and specialists, this means patients may present having already initiated a topical retinoid, potentially altering the initial diagnostic and treatment pathway. While increased accessibility is generally beneficial, clinicians must remain vigilant for cases of self-misdiagnosis or inappropriate use, particularly in patients with more severe inflammatory or nodulocystic acne who require systemic therapies or higher-strength prescription retinoids. The onus will be on pharmacists and clear product labelling to guide appropriate selection, but primary care physicians will inevitably encounter the consequences of both correct and incorrect self-treatment.
From an industry perspective, this move by the FDA for adapalene 0.1% gel, originally developed by Galderma, sets a precedent. It demonstrates a pathway for other well-tolerated, effective prescription dermatologics to transition to OTC status, provided they meet the rigorous safety and consumer comprehension standards. This could open new market segments for pharmaceutical companies and increase competition in the OTC skincare space. However, it also necessitates robust post-market surveillance to monitor for unexpected adverse events or patterns of misuse in a broader, unsupervised population.
For patients, the immediate benefit is convenience and potentially lower cost, bypassing a doctor's visit and prescription fees. This democratisation of a previously prescription-only treatment is a positive step for those with mild to moderate acne. However, it also places a greater responsibility on the individual to understand the product's limitations, potential side effects, and the importance of sun protection. The risk of patients delaying professional medical advice for more severe or persistent acne, mistakenly believing OTC adapalene is sufficient, remains a concern. Education from healthcare providers, even for OTC products, will be crucial to ensure optimal patient outcomes and prevent the exacerbation of conditions that require more intensive intervention.
- The Pivot Adapalene 0.1% gel, a third-generation topical retinoid, is now available without a prescription.
- The Data Clinical trials demonstrated efficacy and safety profiles comparable to prescription use, supporting the OTC switch.
- The Action Clinicians should be aware of increased patient access to adapalene and counsel on appropriate use, especially regarding potential irritation and sun sensitivity.
ART-2026-102
Cite This Article
Team TLSFE. Fda approves otc switch for topical adapalene 0.1% gel. The Life Science Feed. Updated May 27, 2026. Accessed May 27, 2026. https://thelifesciencefeed.com/dermatology/acne-vulgaris/fda-approves-otc-switch-topical-adapalene-0-1-gel.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
References
1. Zaenglein AL, Pathy AB, Schlosser BA, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.e33.
2. Leyden JJ, Stein-Gold L, Weiss J. Why topical retinoids are mainstays of therapy for acne. Dermatol Ther (Heidelb). 2017;7(3):293-304.
3. U.S. Food and Drug Administration. FDA approves first over-the-counter retinoid for acne treatment. FDA News Release. July 8, 2016.
4. U.S. Food and Drug Administration. Guidance for Industry: OTC Drug Monograph Process. FDA. 2019.
5. Cunliffe WJ, Caputo R, Dreno B, et al. Clinical efficacy and safety comparison of adapalene gel 0.1% and tretinoin gel 0.025% in patients with acne vulgaris: a European multicenter trial. J Am Acad Dermatol. 1997;36(6 Pt 2):S126-S130.
6. Lucky AW, Jorizzo JL, DeLeo VA, et al. Adapalene 0.1% gel is as effective as tretinoin 0.025% gel in treating acne vulgaris with less irritation: results of a multicenter, investigator-blinded trial. J Am Acad Dermatol. 1997;36(6 Pt 2):S120-S125.
7. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne Group. J Am Acad Dermatol. 2009;60(5 Suppl):S1-S50.